Recent Updates
Recently added Catalysts
TECH Positive Sentiment Score: 75/100

BIO-TECHNE ANNOUNCES BIOTHERAPEUTIC CHARACTERIZATION STRATEGIC CO-MARKETING AND CO-PROMOTION AGREEMENT Bio-Techne Corporation (NASDAQ: TECH), a leader in automated platforms for biotherapeutic characterization, today announced a co-marketing and...

Key Takeaway: Bio-Techne Corporation (NASDAQ: TECH) has announced a strategic co-marketing and co-promotion agreement aimed at enhancing biotherapeutic characterization. The collaboration involves joint activities including webinars, conference presentations, and the release of an application note. The initiative seeks to integrate the capabilities of both companies to improve laboratory workflows and expedite the development of life-saving therapies. This strategic effort signifies a forward step in the partnership, leveraging combined expertise in the biopharma sector.

Market Sentiment Analysis

POSITIVE FACTORS

  • The partnership aims to accelerate biotherapeutic characterization in biopharma labs.
  • Bio-Techne is committed to providing innovative solutions that empower scientists.
  • The collaboration includes joint activities and presentations at key conferences.

Full Press Release Details

Scientists and commercial team members from both companies participated in several joint activities in October and November 2024 , including the publication of an application note , a webinar , poster presentations, and talks at key conferences including CASSS MS, Festival of Biologics and PEGS EU, and in-person talks at two Bio-Techne User Group Meetings in Boston and San Diego . Moving forward, application scientists from both companies are working on the analysis of additional classes of biomolecules and plan to exhibit the joint results in a poster at upcoming scientific conferences. This work will guide application notes, webinars, and presentations at upcoming Bio-Techne User Group Meetings to co-market each company's advanced biotherapeutic characterization and development process capabilities.
"We are thrilled to see how these new workflows are accelerating biotherapeutic characterization in biopharma labs," said Will Geist , President of the Protein Sciences Segment at Bio-Techne. "Our goal is to continue offering innovative solutions that empower scientists, streamline workflows, and help bring life-saving therapies to market faster."
Explore Bio-Techne's automated biotherapeutic characterization platforms here .
Learn about Waters innovative analytical solutions here .
About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH ) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook , LinkedIn , Twitter or YouTube .
Contact: David Clair , Vice President, Investor Relations & Corporate Development [email protected] 612-656-4416
BioAccord is a trademark of Waters Technologies Corporation.
SOURCE Bio-Techne Corporation

21 %

Frequently Asked Questions

What joint activities occurred in late 2024?

Scientists and commercial teams from both companies engaged in publishing, webinars, and presentations at key conferences.

How will future work be presented?

Future analyses of biomolecules will be showcased in posters at scientific conferences.

What is Bio-Techne's goal?

Bio-Techne aims to provide innovative solutions for faster biotherapeutic market delivery.

What does Bio-Techne specialize in?

Bio-Techne develops tools and reagents for life sciences, aiding drug discovery and diagnostics.

Last updated: Dec 19, 2024